QUINCE THERAPEUTICS INC (QNCX) Stock Income Statement
NASDAQ:QNCX - Nasdaq - US22053A1079 - Common Stock - Currency: USD
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 38.06M | 28.72M | 51.19M | 90.32M | 78.89M | |||
| Research and Development | 19.50M | 9.45M | 25.18M | 60.80M | 61.31M | |||
| Selling, General, and Administrative Expenses | 14.90M | 17.70M | 26.01M | 29.52M | 17.59M | |||
| Operating Income | -38.06M | -28.72M | -51.19M | -90.32M | -78.89M | |||
| Interest Income/Expense | 3.41M | 3.48M | 1.07M | 620.00K | 2.04M | |||
| Other Income/Expense | -1.35M | -374.00K | -1.00M | -250.00K | N/A | |||
| Non Recurring Items | -17.13M | -5.97M | -830.00K | N/A | N/A | |||
| Income Before Taxes | -53.13M | -31.58M | -51.94M | -89.95M | -76.85M | |||
| Income Tax | 131.00K | -197.00K | -280.00K | N/A | N/A | |||
| Net Income | -53.26M | -31.39M | -51.66M | -89.95M | -76.85M | |||
| EBITDA | -37.59M | -28.40M | -50.99M | -89.98M | -78.56M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.25 | -0.84 | -1.54 | -3.03 | -2.63 | |||
| Non GAAP EPS | N/A | N/A | N/A | -3.03 | -2.63 | |||
| Statistics | ||||||||
All data in USD